Fulgent Genetics (FLGT) Receivables (2015 - 2026)

Fulgent Genetics has disclosed Receivables across 12 years of filings, most recently posting $69.3 million for Q1 2026.

• Receivables for Q1 2026 came in at $69.3 million, down 6.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.3 million (down 6.4% YoY), and the FY2025 annual result was $84.8 million, up 19.74% from the prior year.
• Receivables came in at $69.3 million for Q1 2026 at Fulgent Genetics, down from $84.8 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $160.8 million in Q1 2022 to a low of $35.7 million in Q2 2023.
• The 5-year median for Receivables is $70.8 million (2024), against an average of $74.9 million.
• Across the five-year window, Receivables sank 73.24% in 2023 and jumped 61.81% in 2024, its largest moves.
• Fulgent Genetics' Receivables stood at $72.6 million in 2022, then decreased by 27.74% to $52.5 million in 2023, then surged by 34.96% to $70.8 million in 2024, then climbed by 19.74% to $84.8 million in 2025, then fell by 18.27% to $69.3 million in 2026.
• The last three Receivables figures came in at $69.3 million (Q1 2026), $84.8 million (Q4 2025), and $72.6 million (Q3 2025), per Business Quant data.